PKI-166 hydrochloride

Cat. No. M56414

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.

Molecular Weight	366.84
Formula	C20H19ClN4O
CAS Number	2230253-82-2
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related EGFR/HER2 Products
Nimotuzumab Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR.
Matuzumab Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR.
AEE788 AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.
Sapitinib (AZD8931) AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively.
Afatinib Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor.

Catalog